Voltar
Artigo Revisado por pares
BIBTEX RIS

Poster: MDS-090: Phase II Study of the IDH2 Inhibitor Enasidenib in Patients with High-Risk IDH2-Mutated Myelodysplastic Syndromes (MDS)

2021; Elsevier BV; Volume: 21; Linguagem: Inglês

10.1016/s2152-2650(21)01427-0

ISSN

2152-2650

Autores

Sangeetha Venugopal, Courtney D. DiNardo, Koichi Takahashi, Marina Konopleva, Sanam Loghavi, Gautam Borthakur, Amy E. DeZern, Lucia Masárová, Naval Daver, Nicholas J. Short, Yesid Alvarado, Farhad Ravandi, Guillermo Montalban‐Bravo, Koji Sasaki, Ricardo Delumpa, Mikkael A. Sekeres, Bhumika J. Patel, Gail J. Roboz, Hagop M. Kantarjian, Guillermo Garcia‐Manero,

Tópico(s)

Myeloproliferative Neoplasms: Diagnosis and Treatment

Referência(s)